What caused NOVT's Q4 2024 EPS to decline?

Novanta's Q4 2024 EPS decline can be attributed to several key factors: 1. **Organic Revenue Decline**: Despite a 3% organic revenue growth in Q4 2024, the company experienced a 2% decline in organic growth for the full year 2024. This suggests that while there was some growth, it was not enough to offset other challenges, contributing to the EPS decline. 2. **Softness in DNA Sequencing Applications**: A significant factor in Novanta's organic decline was the reduction in sales into DNA sequencing applications. This indicates that performance in this segment had a disproportionate impact on overall earnings, pulling down the average. 3. **Currency Translation Impact**: Novanta faced a $2 million unfavorable FX impact, which could contribute to the overall revenue and profit shortfall. This highlights the challenges of operating globally and the impact of currency fluctuations on financial performance. In summary, Novanta's Q4 2024 EPS decline is primarily due to a combination of organic revenue decline, softness in specific market segments, and currency translation impact.